

INDEX

- Adaptive immunity, 58, 82, 171, 186, 205, 207, 219, 221, 228, 255, 406
- Adenovirus, 83, 88, 201, 221, 223, 226, 228, 229, 231, 282
- Adjuvant, 58, 84–87, 177–181, 186, 191, 194, 196, 201, 203–205, 208, 225, 233, 236, 257, 259–262, 265, 277, 280, 281, 285, 287, 288, 289, 291, 297, 300, 305, 306, 308–311, 332, 334, 337, 410, 414, 415, 417, 418, 431, 473, 474, 476, 477, 488, 489
- Adoptive T cell therapy, 47
- Alemtuzumab (Campath), 332, 333, 454, 465, 469, 470
- Allogeneic whole cell vaccine, 278
- Alpha-galactosyl ceramide (α GalCer), 56–61
- Alphaviruses, 221, 229–230
- ALVAC, 225, 227, 282
- Antibody
- chimeric, 324, 353, 460
 - light chain, 322, 323, 455
 - monoclonal, 4, 11, 46, 92, 94, 123, 127, 193, 199, 200, 203, 204, 206, 217, 239, 263, 297–300, 303, 304, 306308, 321, 332, 366, 368, 372, 373, 397, 419, 420, 434, 453–477
 - pharmacokinetics, 325, 326
 - variable chain, 353
- Antibody dependent cell-mediated cytotoxicity (ADCC), 299, 310, 323, 324, 334, 419, 453, 457, 462
- Antigen, 18, 21, 22, 173, 175, 177, 178, 196, 258, 304, 348
- cancer-testis, 18, 21–22, 173, 175, 177, 178, 196, 258, 304, 348
 - differentiation, 12, 18, 23, 131, 175, 176, 196–198, 202, 207, 368, 376
 - overexpressed, 12
 - shed, 275, 276, 277, 278, 280, 282, 288, 291
- Antigen presentation, 38, 83, 89, 90, 92, 125, 132, 153, 171, 253, 254, 258, 284, 285, 365, 379, 409, 410, 486, 493
- Antigen-presenting cell, 34, 37–39, 41–46, 48, 55, 57, 58, 61, 62, 68, 70, 71, 81–82, 94, 153, 157, 171, 172, 183, 184, 191, 194, 195, 203–206, 221, 222, 230, 234, 237, 238, 251, 252, 256, 263, 266, 279–282, 284–286, 349–351, 366, 368, 377, 378, 395, 406, 410, 411, 420, 486–488
- Antigen processing and presentation, 34, 35, 38, 47, 126, 127, 254
- Apoptosis, 25, 37, 45, 69, 70, 78, 81, 85, 134, 150–152, 154, 155, 157, 158, 160, 204, 230, 231, 256, 265, 266, 284, 324, 334, 408–410, 419, 420, 433, 434, 457, 462, 469, 470, 485–492, 494
- Autoimmunity, 12, 24, 25, 60, 62, 75, 77, 78, 80, 198, 205, 207, 221, 251, 258, 264, 284, 304, 363, 370, 372, 376, 379, 411, 412, 420, 433, 434, 441, 491
- Autologous whole cell vaccines, 278
- B cell, 33, 34, 43, 45, 47, 57, 58, 72, 74, 78–81, 86, 87, 89, 92–95, 125, 133, 147, 155, 176, 194, 197, 200, 201, 203, 206, 321, 322, 324, 326, 331, 332, 336, 347, 349, 350, 353, 363, 377–378, 399, 410, 412, 414, 456, 462, 465–470
- B7 family, 44, 45, 69, 77, 255, 378, 494
- B7H, 44, 69, 77
- Bacille Calmette Guérin (BCG), 11, 72, 219, 233, 235, 236, 238, 281, 285–287, 289, 306, 309
- Bacterial vaccine, 6, 217–240
- BCG, 72, 233, 235, 236, 238, 281, 285–287, 290, 306, 309
 - Clostridium, 235, 238, 239
 - Listeria, 235, 237, 238, 255, 262
 - Salmonella, 238, 308
 - Shigella, 238
- Bevacizumab (Avastin), 263, 332, 334, 454, 456, 457, 472–475
- Bone marrow transplantation, 68, 264, 336
- Cancer-testis antigens, 12, 18, 21–22, 173, 175, 177–178, 196, 258, 304, 348
- Capillary leak syndrome, 432, 443–447
- Carbohydrate antigens, 291, 297–301, 304–306, 310, 311
- Carbonic anhydrase IX (CA IX), 439, 440

- Carcinoembryonic antigen (CEA), 18, 21, 23, 72, 73, 173, 196, 197, 199, 202, 222–225, 227, 228, 234, 235, 300, 304, 353
- CD1d, 55–60, 94, 254
- CD4, 18, 22, 33, 34, 36–38, 44–48, 55, 57, 67, 69, 71, 79, 80, 82, 88, 89, 131, 132, 136, 148, 149, 179, 182, 185, 194, 203, 204, 206, 207, 222, 237, 253–256, 260, 261, 264, 279, 283, 284, 344, 346, 350–352, 366, 367, 369–373, 376–378, 396, 397, 401, 412, 433, 434, 486, 489, 493
- CD8, 24–26, 34, 36–39, 43–47, 55, 60, 61, 67, 69, 71, 73, 74, 78, 80–82, 87–89, 92, 132, 136, 148, 149, 155, 177, 180, 181, 185, 194, 198, 200, 201, 203, 205–207, 222–225, 228, 235, 237, 253, 256, 261, 266, 279, 283, 284, 344, 346, 350, 352, 363, 365–370, 372, 374, 377, 395–398, 411, 414, 433, 434, 486–494
- CD20, 197, 200, 324, 326, 330–333, 336, 337, 353, 454, 456, 460, 462, 466–468
- CD25, 47, 48, 57, 75, 88, 149, 175, 207, 220, 264, 294, 330, 369–373, 376, 377, 379, 433, 492, 493
- CD27, 45, 46, 78, 79, 82, 182, 207, 364
- CD28, 41–46, 68–71, 77, 80, 149, 175, 183, 205, 206, 255, 264, 323, 346, 350, 353, 364, 366, 367, 372, 377, 378, 397, 420, 490
- CD33, 35, 155, 325, 326, 328, 332, 336, 353, 397, 454, 456, 465, 469
- CD40, 44, 45, 47, 48, 58, 69, 81, 175, 182, 205, 206, 228, 234, 235, 254, 256, 262, 349, 410, 487, 493
- CD40 ligand, 44, 59, 175, 203, 205, 254
- CD52, 332, 333, 454, 469, 470
- CD70, 45, 46, 69, 78, 79
- CD80 (B7.1), 42–44, 70, 153, 175, 203, 205, 206, 351, 366, 378, 410, 489
- CD86 (B7.2), 42–44, 70, 153, 175, 201, 203, 205, 206, 366, 410, 489
- CD122, 86, 372, 433
- CD132, 85, 372, 433
- CD152, 70
- Cell signaling, 203, 204
- Central supramolecular activation cluster (C-SMAC), 42, 256
- Cetuximab (Erbix), 332, 334, 335, 454, 456, 457, 460, 461, 473, 475, 476
- Checkpoint blockade, 363–390
- Chemokine, 39, 61, 82, 95, 160, 161, 172, 204–206, 220, 255, 258, 262, 263, 281, 411
- Chemokine receptor, 59, 160, 220, 370, 411, 412
- Chemotherapy
 combination, 485
 host conditioning, 353
 lymphodepleting, 176, 265, 266, 373, 494
- Chimeric antibody, 324, 353, 460
- Clinical trials, 21, 22, 24–26, 46–48, 68, 71–73, 75, 77, 81, 82, 84–86, 91–95, 171, 179, 182, 184, 185, 194, 196, 201, 202, 205–207, 221, 227–233, 236, 238–240, 257, 266, 267, 282, 283, 285, 288, 298, 299, 303, 308, 309, 311, 321, 323, 330, 343, 345, 346, 351, 353–355, 365, 370, 374, 375, 395, 396, 398, 420, 431, 432, 435–439, 453, 454, 467, 468, 471, 477, 493
- Clostridium, 235, 238, 239
- Combination therapy, 222, 224, 226, 236, 239, 263
- Complement dependent cytotoxicity (CDC), 299, 306–308, 310, 453, 457, 462
- Complementarity determining region (CDR), 40, 322, 326, 346, 455, 460–462
- Costimulatory molecule, 43, 69, 137, 207, 220, 221, 228, 233, 258, 262, 265, 282, 346, 349, 350, 353, 397, 410, 434, 487
- CpG, 21, 22, 180, 191, 194, 196, 199, 202, 220, 254, 261, 262, 266, 281, 369, 379, 487, 489, 493
- Cross presentation, 26, 37, 38, 47, 131, 203, 253, 254, 260–262, 266, 279, 350, 486–488, 493
- Cytokine, 34, 43, 45, 46, 48, 55, 57–59, 61, 67, 70, 79, 82–84, 86–90, 92, 94, 95, 129, 130, 135–137, 147, 150–153, 157–161, 172, 176–179, 181, 182, 193, 204–206, 220, 221, 228, 232, 233, 235, 236, 239, 251, 255, 256, 258, 259, 261–263, 265, 266, 276, 280, 281, 283, 284, 290, 324, 350, 351, 353–355, 364, 367, 370, 373, 377, 393–400, 406–413, 431–433, 436, 453, 457, 458, 487, 489, 493, 494
- Cytokine flow cytometry (CFC), 177, 181, 393
- Cytotoxic T lymphocyte (CTL), 34, 88, 89, 94, 123, 126, 175, 176, 191, 204, 206, 256, 257, 344, 486
- Cytotoxic T lymphocyte-associated protein 4 (CTLA-4), 70, 183, 191, 206, 207, 364, 420
- Danger signals, 146, 157, 159, 186, 194, 199, 206, 221, 254, 265, 488, 489, 493
- Dendritic cell
 Langerhan's cells, 252, 257, 262
 maturation, 91, 489
 myeloid, 46, 47, 153, 251, 410
 plasmacytoid, 153, 251, 262, 407
 vaccines, 194, 251–267, 379
- Denileukin diftitox (ONTAK), 264

- Differentiation antigens, 12, 18, 22, 23, 131, 175, 176, 196–198, 202, 207, 368, 376, 410
- DNA vaccines, 74, 87, 88, 193–208, 234, 261–263, 368
- Donor lymphocyte infusion (DLI), 345–347
- Dosimetry, 327–329, 468
- Edrecolomab (Panorex, 17-1A), 473, 476
- Endoplasmic reticulum, 18, 36–38, 123, 126, 127, 253
- Endosome, 38, 126, 253, 326, 372, 489
- Enzyme-linked immunosorbent assay (ELISA), 177, 180, 191, 289, 306–308, 394
- Enzyme-linked immunospot assay (ELISPOT), 75, 177, 182, 191, 202, 289, 393–396, 398, 399, 402, 419
- Epidermal growth factor receptor (EGFR), 199, 324, 332, 334, 335, 420, 471, 475, 476
- Epitope, 17–26, 35, 37, 38, 71, 79, 127, 148, 154, 155, 175, 176, 181, 182, 184–186, 194, 196, 198–200, 203, 206, 221, 225, 234, 254, 258, 261, 276–278, 289–291, 299, 302, 303, 305, 308–310, 344, 348–352, 398, 411, 419
- 4-1BB, 69, 78–80, 82, 207, 350, 351, 364, 379
- Fowlpox virus, 282
- FoxP3, 149, 369–371
- Gangliosides, 57, 131, 150, 151, 154, 158, 219, 254, 279, 283, 298, 300, 302, 305, 308, 310, 417, 419, 458
- Ganglioside vaccine, 306
- Gemtuzumab ozogamicin (Mylotarg), 332, 335, 458, 465, 469
- Glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR), 69, 82, 149, 204, 206, 207, 364, 369, 373, 379
- Glycolipids, 55–57, 297–300, 302, 303, 306, 310
- Glycoproteins, 25, 35, 85, 92, 200, 298, 303, 305, 329, 333
- Granulocyte-macrophage colony stimulating factor (GM-CSF), 39, 46–48, 57, 72, 74, 76, 81, 82, 84–86, 160, 175, 178, 179, 191, 201, 203, 205, 220, 222, 224–226, 228, 257, 281, 283, 344, 365, 368, 369, 373, 375, 379
- Heat shock proteins, 184, 185, 191, 204, 253, 262, 265, 277, 487, 489, 493
- Helper T cells, 33, 182, 234, 372
- Herpes virus, 80, 489
- Herpes virus entry mediator (HVEM), 45, 46, 69, 80, 81, 364, 378
- Heteroclitic epitope, 198–199, 200
- History of immunotherapy, 6
- Host conditioning, 353
- Human anti-human antibody (HAHA), 460
- Human anti-mouse antibody (HAMA), 327, 419, 460, 467, 468
- Human leukocyte antigen (HLA), 18–20, 22–26, 35, 72–75, 123–137, 148, 153, 155, 171, 173, 175, 177, 180–182, 185, 191, 194, 200, 225, 235, 258, 266, 277, 278, 288, 351, 395, 410, 438
- Human papilloma virus, 11, 123, 130, 132, 155, 173, 175, 181, 191, 196, 197, 222, 225, 227, 235, 258, 262
- Hybridoma technology, 321, 458–461
- Ibritumomab tiuxeten (Zevalin), 332, 337, 458, 462, 464, 467, 468
- Imiquimod (Aldara), 178, 179, 204, 259, 262, 281, 379
- Immune monitoring, 258
- Immunoglobulin, 33, 68, 123, 126, 197, 200, 201, 205, 206, 260, 321, 322, 324, 352, 353, 364, 377, 378, 454
- Immunological synapse, 40–43, 254, 256, 367
- Immunoproteasome, 18
- Immunosurveillance, 131, 219, 406, 490, 491
- Immunotherapy, 3–12, 17, 18, 26, 40, 47, 48, 67, 68, 71, 73, 78–84, 86–88, 91, 93, 94, 129, 131, 132, 135, 136, 171, 172, 175–177, 183–185, 193, 199, 200, 202, 207, 217–219, 222, 224, 229, 230, 233, 234, 236, 239, 240, 257, 260, 266, 275–277, 281, 291, 300, 304, 328, 337, 348, 353, 368, 369, 396, 431, 437–439, 448, 468, 485, 486, 492–494
- Indoleamine 2, 3-dioxygenase (IDO), 48, 147, 150, 366, 367, 370, 413
- Inducible co-stimulator (ICOS), 44, 46, 47, 69, 77, 364
- Infection, 3–7, 12, 18, 34, 37, 79, 94, 147, 152, 155, 156, 172, 221, 223, 228, 229, 231–233, 237, 238, 259, 261, 280, 282, 299, 304, 309, 310, 333, 350, 365, 366, 405–407, 410, 415, 432, 434, 435, 440, 441, 446, 470, 489
- Inflammation, 39, 45, 80, 145, 146, 156, 158, 159, 161, 220, 254, 299, 366
- Innate immunity, 55, 156, 196, 199, 203, 206, 369, 409, 489
- Interferons
alpha, 11, 82, 177, 193, 252, 281, 306, 411, 436

- gamma, 34, 57, 61, 71, 125, 175, 191, 281, 283, 284
 Type I, 353, 354, 405–412, 414, 418, 419, 487
 Type II, 405, 407, 409
 Interleukin-2, 11, 34, 43, 55, 57, 70, 72, 75–77, 81, 82, 85–89, 91, 135, 148, 175–177, 179, 182, 203, 205, 222, 224–226, 228, 234, 235, 239, 264, 265, 281, 283, 324, 344, 346, 347, 351, 353, 354, 370, 372, 373, 375, 397, 411, 413, 431–448, 493, 494
 Interleukin-7, 83, 85, 86, 256, 265, 266, 283, 354, 396, 433, 493, 494
 Interleukin-10, 44, 45, 48, 70, 73, 76, 78, 89, 90, 92–94, 130, 147, 148, 150, 152, 160, 172, 175, 219, 220, 229, 261, 264, 369, 370, 378, 407, 487, 492
 Interleukin-12, 47, 59, 61, 79, 82, 86–89, 153, 179, 180, 194, 203–205, 228, 239, 255–257, 261–264, 281, 283, 411, 487, 492
 Interleukin-13, 57, 60, 89, 90, 94, 95, 175, 256
 Interleukin-15, 83, 85–87, 135, 153, 203, 205, 239, 255–257, 265, 266, 351, 354, 396, 410, 433, 493, 494
 Interleukin-18, 83, 87, 88, 203, 205, 234, 256, 283

 Langerhan's cells, 252, 257, 262
 Listeria, 235, 237, 238, 255, 262
 Lymphodepleting chemotherapy, 176, 265, 266, 373, 494

 Major histocompatibility complex, 3, 9, 10, 17–20, 23, 25, 33–40, 48, 55, 67, 68, 71, 89, 123–126, 129–132, 135, 136, 151, 155, 175–177, 180–185, 192, 194, 195, 198, 199, 203, 204, 206, 218, 220, 221, 230, 237, 251, 253, 254, 258, 260, 261, 264, 265, 393
 Measles virus, 221, 223, 231
 Monoclonal antibody therapy, 321–342, 463, 472
 Myeloid dendritic cells, 46, 47, 153, 251, 410

 Natural killer (NK) cells, 11, 41, 55, 88, 123, 179, 192, 204, 255, 282, 323, 406, 432, 457, 490
 Natural killer T (NKT) cells, 55, 87, 255, 490
 Newcastle Disease virus (NDV), 221, 223, 226, 231, 232
 NKG2D, 126, 135, 485, 490, 491, 493, 494
 Non-classical HLA, 124, 125, 132, 134, 136, 137

 Oncolytic viruses, 230, 231, 233
 Overexpressed antigens, 12
 OX40, 45–47, 69, 79, 82, 207, 228, 364, 373, 379

 Peptide vaccine, 22, 46, 75, 84, 86, 177, 180, 182, 183, 194, 351, 375, 460
 Phage display, 155, 326, 458–461
 Plasmacytoid dendritic cell, 407
 Polysialic acid vaccine, 309, 310
 Polyvalent vaccine, 277, 305, 309–311, 396
 Poxviruses, 221, 222, 224, 227, 228
 Programmed death 1 (PD-1), 45, 47, 69, 78, 255, 256, 368, 377–379
 Protein vaccine, 171–191
 Proteosome, 38

 Radiation therapy, 6, 74, 231, 265, 298, 310, 332, 337, 418, 440
 Radioimmunotherapy, 321, 327, 330, 336, 337, 468
 Real time polymerase chain reaction (rt-PCR), 21, 400
 Regulatory T cell, 11, 48, 57, 60, 69, 70, 73, 88, 89, 93, 123, 136, 147, 149, 150, 175, 196, 204, 207, 255, 264, 266, 344, 353, 354, 364, 369–374, 378, 379, 432, 433, 448, 493, 494
 Rituximab (Rituxan), 93, 193, 200, 324, 331–333, 337, 453, 454, 457, 458, 460–464, 466–468, 470

 Salmonella, 238, 308
 Serological analysis of gene expression (SEREX), 20, 172, 192, 348
 Shed antigen, 275, 277, 278, 280, 282, 288, 290, 291
 Shigella, 238
 Single nucleotide polymorphism (SNP), 123, 132, 412
 Stroma, 131, 156, 159, 414, 492
 Survivin, 19, 24, 25, 197
 Syngeneic mice, 10

 T cell
 CD4, 18, 22, 33, 34, 36–38, 44–48, 55, 57, 67, 69, 71, 79, 80, 82, 88, 89, 131, 132, 136, 148, 149, 179, 182, 185, 194, 203, 204, 206, 207, 222, 237, 253–256, 260, 261, 264, 279, 283, 284, 344, 346, 350–352, 366, 367, 369–373, 376–378, 396, 397, 401, 412, 433, 434, 486, 489, 493

- CD8, 24–26, 34, 36–39, 43–47, 55, 60, 61, 67, 69, 71, 73, 74, 78, 80–82, 87–89, 92, 132, 136, 148, 149, 155, 177, 180, 181, 185, 194, 198, 200, 201, 203, 205–207, 222–225, 228, 235, 237, 253, 256, 261, 266, 279, 283, 284, 344, 346, 350, 352, 363, 365–370, 372, 374, 377, 395–398, 411, 414, 433, 434, 486–494
- cytotoxic, 89, 93, 94, 205, 370, 377, 393, 439, 456
- effector, 44, 45, 352, 353, 378, 379
- helper, 399
- memory, 83, 185, 256, 399
- regulatory, 11, 48, 57, 60, 69, 70, 73, 88, 89, 93, 123, 136, 147, 149, 150, 175, 196, 204, 207, 255, 264, 266, 344, 353, 354, 364, 369–374, 378, 379, 432, 433, 448, 493, 494
- tolerance, 47, 59, 368, 378
- T cell receptor (TCR), 18–20, 23, 33, 35, 39–45, 48, 55–57, 60, 68, 70, 82, 123, 127, 148, 150–152, 154, 175, 176, 179, 181, 192, 197, 200, 207, 221, 254–256, 258, 265, 323, 345, 346, 349, 352, 363, 364, 366, 367, 377, 397, 398, 434
- Tetramers, 20, 25, 56, 75, 148, 177, 180–182, 201, 202, 290, 393, 394, 397, 398
- Thymic selection, 180
- Tolerance, 12, 34, 39, 47, 48, 59, 68, 153, 156, 172, 175, 180, 183, 185, 186, 196–199, 206, 218, 227, 228, 230, 255, 256, 261, 264, 280, 281, 364–366, 368, 373, 376, 378, 379, 411, 414, 487
- Toll-like receptor (TLR), 3, 7, 178, 180, 194, 202–204, 206, 219, 220, 254, 257, 259, 261, 262, 266, 280, 281, 369, 406, 407, 410, 487, 489, 493
- Tositumomab (Bexxar), 326, 332, 336, 337, 454, 458, 465, 468
- Transforming growth factor beta (TGF- β), 88, 175, 256, 369
- Transporter associated with antigen processing (TAP), 18, 36–39, 123–127, 129, 132, 253
- Trastuzumab (Herceptin), 199, 332, 334, 454, 456, 457, 471, 472, 474
- Tumor antigen, 8, 10, 11, 17–31, 34, 35, 47, 48, 71, 73, 82–84, 88, 123, 147, 150, 171–173, 177, 179, 181–185, 193, 194, 196, 197, 199, 200, 206, 207, 224, 234, 257–259, 262–265, 276, 278, 280, 283, 284, 291, 297, 304, 305, 327, 348–350, 365, 369, 374, 375, 379, 394, 395, 398–401, 411, 456, 485–488, 493, 494
- Tumor-associated macrophage (TAM), 123, 131, 152, 155, 157, 159
- Tumor infiltrating lymphocyte (TIL), 123, 131, 134, 135, 145, 148–152, 154, 155, 160, 171, 176, 177, 183, 192, 194, 218, 257, 264, 266, 345–347, 351, 354, 369, 370, 373, 431, 433, 447
- Tumor lysate, 260, 264, 281, 287, 365
- Tumor microenvironment, 34, 44–48, 130, 145–161, 182, 220, 263, 370, 407, 447
- Tumor necrosis factor (TNF), 3, 4, 7, 37, 57, 59, 68, 69, 81, 83, 86, 88, 123, 136, 149, 159, 179, 192, 207, 228, 232, 235, 239, 254, 257, 262, 324, 395, 397, 412, 413, 434, 439, 447, 458, 491
- Tumor necrosis factor receptor family (TNFR), 43, 45, 78, 82, 206, 364, 373, 409
- Tumor necrosis factor related apoptosis-inducing ligand (TRAIL), 59, 150, 256, 409, 485, 491–494
- Uric acid, 489, 493
- Vaccines
- bacterial, 6, 217–240
 - dendritic cell, 194, 251–267, 379
 - DNA, 74, 87, 88, 193–208, 234, 261–263, 368
 - ganglioside, 306
 - peptide, 22, 46, 75, 84, 86, 177, 180, 183, 194, 351, 375, 460
 - polysialic acid, 309, 310
 - polyvalent, 277, 305, 309–311, 396
 - protein, 171–186
 - viral, 73, 84, 194, 221, 230, 395
 - whole cells, allogeneic, 278, 285
 - whole cells, autologous, 277
- Vascular endothelial growth factor (VEGF), 131, 134, 159, 204, 219, 220, 263, 324, 332, 334, 454, 456, 457, 474
- Viral vaccines, 73, 84, 194, 221, 230, 395
- Whole cell vaccines, 72, 275–291, 376